마이크로니들형 인플루엔자 백신 시장 : 제품 유형별, 백신 유형별, 인플루엔자 유형별, 세계 예측(2024-2032년)

Microneedle Flu Vaccine Market size will witness 6.1% CAGR from 2024-2032, driven by rising research activities for the development of more effective and efficient microneedle designs. For example, in January 2023, CD Formulation introduced its dissolving microneedle preparation services for enhancing drug delivery efficiency. Advancements in materials, such as biodegradable polymers and metals, are enhancing the delivery of the flu vaccines while reducing waste. Innovations in coatings used on microneedles are also improving the stability and efficacy of vaccines, adding to the product demand.

The microneedle flu vaccine market is segmented into product type, vaccine type, flu type, and region.

In terms of product type, the industry value from the coated microneedle segment may witness strong growth from 2024 to 2032. As coated microneedle patches can be self-administered, they reduce the need for healthcare professionals, making it easier to vaccinate the large population quickly. The ongoing advances in microneedle technology, materials science, and vaccine formulation area also driving the development of more effective and user-friendly coated microneedle vaccines.

Based on flue type, the microneedle flu vaccine market from the influenza B segment is expected to expand at robust CAGR from 2024-2032. These vaccines are designed to be less painful, easier to administer, and potentially more effective than traditional intramuscular injections. With positive regulatory frameworks, microneedle vaccines have turned standard solutions for influenza vaccination for improving public health outcomes and reducing the burden of seasonal flu epidemics. The ongoing R&D is also likely to yield more effective and user-friendly vaccination options.

Regionally, the Asia Pacific microneedle flu vaccine industry is projected to witness lucrative CAGR from 2024 to 2032 due to the surging government support. The focus on painless, convenient, and cost-effective vaccination methods in the region is making microneedle vaccines a promising solution for improving public health outcomes. The presence of a large and diverse population with varying levels of access to healthcare will also favor the product preference in APAC.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of influenza and viral infections
    • 3.2.1.2 Ease of administration
    • 3.2.1.3 Growing investment in research and development of microneedle technology
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Complications and risks associated with microneedles
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Solid microneedle
• 5.3 Hollow microneedle
• 5.4 Coated microneedle
• 5.5 Dissolving microneedle

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Trivalent flu vaccine
• 6.3 Quadrivalent flu vaccine

Chapter 7 Market Estimates and Forecast, By Flu Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Influenza A
  • 7.2.1 H1N1
  • 7.2.2 H3N1
• 7.3 Influenza B

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 3M
• 9.2 Becton, Dickinson and Company
• 9.3 Corium International, Inc.
• 9.4 CosMED Pharmaceuticals Co., Ltd
• 9.5 FluGen, Inc
• 9.6 Sanofi